The group will use a vegetarian diet with the active compactor N-111.

The group will use a non-vegetarian diet with the active compactor N-111.

The group will use a vegetarian diet with a placebo.

The group will use a non-vegetarian diet with a placebo.

The group will use a vegetarian diet without the active compactor N-111 or the placebo.

he group will use a non-vegetarian diet without the active compactor N-111 or the placebo.

Dietary Supplement: N-111

Placebo

EA Jeppsen, MD

The study will look at the end result of 2 types of diets effect on treatment outcome of cancer patients using N-111.

The study will be evaluated during a double blind, placebo-controlled evaluation of the effect diet has on the response of patients taking N-111 who are on a vegetarian diet vs a non-vegetarian diet or a placebo. This will involve assessing the patients progress or lack thereof over a 3-month period of time as outlined in Outcome Measures section below.

Active product (N-111) and placebo will be in identical packets with the contents of identical weight, color and texture.

Diet Effect on Cancer Treatment Outcome

A Study on the Effect Diet Has Affecting the Response of Patients Taking N-111 Who Are on a Vegetarian Diet vs a Non-vegetarian Diet or a Placebo

Change in blood levels (CA, CMP, CBC, CEA, Lipids, CRP) from base line to the end of month 3.

Optimal Health Research

Symptoms and General Pathology

All Conditions

Nervous System Diseases

Rare Diseases

Syndrome

Chronic Pain

Pain

Neurologic Manifestations

Chronic Graft Versus Host Disease

Central Nervous System Depressants

All Drugs and Chemicals

Anti-Arrhythmia Agents

Channel Blockers

Analgesics

Anticonvulsants

Reproductive Control Agents

Bone Density Conservation Agents

Bupivacaine

Magnesium Sulfate

Anesthetics

Anesthetics, Local

Calcium

Calcium Channel Blockers

Calcium, Dietary

Hormones

Tocolytic Agents

The patients will receive 20 ml of 0.5% bupivacaine plus 150 mg magnesium sulphate in 0.9% normal saline with a total volume of 25 ml.

The patients will receive 20 ml of 0.5% bupivacaine plus 5 ml 0.9% normal saline with total volume 25 ml

assess the pain intensity of magnesium sulphate as an adjuvant to bupivacaine in serratus anterior plane block for modified radical mastectomy

magnesium sulphate

bupivicaine

Rehab A. Abd Elaziz, Ass. Prof.

Rehab A. Abd Elaziz, Ass.Prof.

Modified radical mastectomy may be associated with severe post-operative pain, leading to chronic pain syndrome which usually requires optimal perioperative pain management.

Patients will be randomly into two equal groups (40 patients each) according to the adjuvant added to the local anesthetic (bupivacaine) in the serratus anterior plane block using a computer-generated random numbers concealed in sealed opaque envelopes. Group B: The patients will receive 20 ml of 0.5% bupivacaine plus 5 ml 0.9% normal saline with total volume 25 ml. Group BM: The patients will receive 20 ml of 0.5% bupivacaine plus 150 mg magnesium sulphate in 0.9% normal saline with a total volume of 25 ml.

Magnesium Sulphate to Bupivicaine in Serratus Anterior Plane Block in Modified Radical Mastectomy

Effectiveness of Adding Magnesium Sulphate to Bupivicaine in Ultrasound Guided Serratus Anterior Plane Block in Patients Undergoing Modified Radical Mastectomy

Alexandria University

Assisstant Professor of Anesthesia

Neoplasms

Skin and Connective Tissue Diseases

Breast Neoplasms

Breast Diseases

Skin Diseases

Antioxidants

group I of 15 women with benign breast lesion

DNA extraction and genotyping of cytochrome P450-2D6\*4 gene using conventional PCR followed by restriction enzyme (Mva1) digestion. Separated plasma was used for measurement of plasma malondialdehyde(MDA)concentration, total plasma antioxidant capacity and plasma ferretin level.

pcr and serum markers for breast cancer

wagih m ghnnam

Aymen z El Samanoudy

The aim of our study is to investigate the potential role of the CYP2D6\*4 polymorphism in breast cancer and furthermore to assess the role of oxidative stress, antioxidant capacity and ferretin in pathogenesis of breast cancer in different CYP2D6\*4 genotypes

Breast cancer is the most common malignancy among women and the second highest cause of cancer death. Nevertheless most of the breast cancer is sporadic with no family history of the disease, Enhanced CYP2D6 activity has been related to malignancies of the bladder, liver, pharynx, and stomach and, especially, to cigarette-smoking-induced lung cancer. Data support that increased formation of reactive oxygen species (ROS) may play an important role in carcinogenesis Numerous in vitro experiments show that ROS damages DNA, inducing premutagenic modifications of nucleotides and promoting oxidation of proteins and lipid per oxidation The aim of our study is to investigate the potential role of the CYP2D6\*4 polymorphism in breast cancer and furthermore to assess the role of oxidative stress, antioxidant capacity and ferretin in pathogenesis of breast cancer in different CYP2D6\*4 genotypes.patients and methods : This study included 31 women admitted to the general surgery department, Mansoura University Hospital. group I consists of 15 women with benign breast lesion, group II composed of 16 women with cancer breast and 13 healthy women with matched age and clinically free were taken as a control group. DNA extraction and genotyping of cytochrome P450-2D6\*4 gene using conventional PCR followed by restriction enzyme (Mva1) digestion. Separated plasma was used for measurement of plasma malondialdehyde(MDA)concentration, total plasma antioxidant capacity and plasma ferretin level.Results homozygous genotype of 2D6\*4 represent 56.25 %( 9/16) of breast cancer group with lower wild type (31.25%-5/16), while it represent 33.3 %( 5/15) of begnine breast lesion group and 15.3(2/13) of the control group. Where the wild type represent the majority of cases (61.15%-8/13) in the control group and 46.6%-7/15) in the begnine breast lesion group.

statistically significant increase in plasma ferretin and MDA mean levels in breast cancer group than begnine breast lesion and the control groups .Also, there is an increase in plasma total antioxidant activity in breast cancer group than the control group with nonstatistical difference between the breast cancer and the benign breast lesion groups .

Conclusion CYP2D6\*4 genotype polymorphism interacting with plasma malondialdehyde (MDA) oxidative stress and plasma ferretin level may have a role in the pathogenesis of breast cancer

Study title	NCT ID	Conditions	Interventions	Eligibility	Organization
Diet Effect on Cancer Treatment Outcome	NCT05410002	Cancer Breast Cancer Prostate	Dietary Supplem... Placebo	25 Years - 80 Years	Optimal Health Research
Magnesium Sulphate to Bupivicaine in Serratus Anterior Plane Block in Modified Radical Mastectomy	NCT04429893	Cancer Breast Chronic Pain Sy...	magnesium sulph... bupivicaine	20 Years - 70 Years	Alexandria University
Magnesium Sulphate to Bupivicaine in Serratus Anterior Plane Block in Modified Radical Mastectomy	NCT04429893	Cancer Breast Chronic Pain Sy...	magnesium sulph... bupivicaine	20 Years - 70 Years	Alexandria University
Role of Cytochrome P450 2D6 (CYP2D6) *4 Polymorphism,in Malignant Breast Diseases	NCT00539422	Breast Cancer	pcr and serum m...	33 Years - 63 Years	Mansoura University
Role of Cytochrome P450 2D6 (CYP2D6) *4 Polymorphism,in Malignant Breast Diseases	NCT00539422	Breast Cancer	pcr and serum m...	33 Years - 63 Years	Mansoura University

Spots Global Cancer Trial Database for cancer breast